검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | 12-Day Production of Car-T Cells (12-Day Production of Car-T Cells) Medical College of Wisconsin·Non Hodgkin Lymphoma (NHL) 2 trials |
|---|---|
Overview Program | 12-Day Production of Car-T Cells |
Overview Company | Medical College of Wisconsin |
Overview Modality | CGT |
Overview Target | Non Hodgkin Lymphoma (NHL) |
Overview Indication | Non Hodgkin Lymphoma (NHL); Mantle Cell Lymphoma (MCL) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted CD19 chimeric antigen receptor |
MoA Biomarker | CD20 expression |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | Grade 1 to 2 immune effector cell-associated neurotoxicity syndrome occurred in 2 patients and resolved spontaneously. |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse.. The point-of-care, automated manufacturing of chimeric antigen receptor (CAR) T cells can reduce the waiting window and increase the therapy accessibility to patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) as compared with commercially availabl… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 11 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | 12-Day Production of Car-T Cells (12-Day Production of Car-T Cells) Medical College of Wisconsin·Non Hodgkin Lymphoma (NHL) 2 trials |
|---|---|
Overview Program | 12-Day Production of Car-T Cells |
Overview Company | Medical College of Wisconsin |
Overview Modality | CGT |
Overview Target | Non Hodgkin Lymphoma (NHL) |
Overview Indication | Non Hodgkin Lymphoma (NHL); Mantle Cell Lymphoma (MCL) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted CD19 chimeric antigen receptor |
MoA Biomarker | CD20 expression |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | Grade 1 to 2 immune effector cell-associated neurotoxicity syndrome occurred in 2 patients and resolved spontaneously. |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse.. The point-of-care, automated manufacturing of chimeric antigen receptor (CAR) T cells can reduce the waiting window and increase the therapy accessibility to patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) as compared with commercially availabl… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 11 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교